AgingResearch.NewsJoin free

CXCR4 antagonist

CXCR4 antagonist has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Mar 20, 2022: “Skeletal muscle mitoribosomal defects are linked to low bone mass caused by bone marrow inflammation in male mice”.

Intervention

1 paper studies it2 findingsUpdated

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Japan Society for the Promotion of Science and 1 more
  • 2 of 2 findings with company ties
  • Animals1

What did studies of CXCR4 antagonist find?

2

Studies of CXCR4 antagonist measured 2 outcomes; the most studied are bone mass (1 study) and bone marrow inflammation (1).

Bone mass

upin mice1

1 study

  1. CXCR4 antagonist increases bone mass in mice.

    “Antagonism of CXCR4 attenuated BM inflammation and increased bone mass in MKO mice.”

    Animalsin MKO micebonemales

    Skeletal muscle mitoribosomal defects are linked to low bone mass caused by bone marrow inflammation in male mice

    Journal of cachexia, sarcopenia and muscle

Bone marrow inflammation

downin mice1

1 study

  1. CXCR4 antagonist decreases bone marrow inflammation in mice.

    “Antagonism of CXCR4 attenuated BM inflammation and increased bone mass in MKO mice.”

    Animalsin MKO micebone marrowmales

    Skeletal muscle mitoribosomal defects are linked to low bone mass caused by bone marrow inflammation in male mice

    Journal of cachexia, sarcopenia and muscle

Latest

Related